Increased heart rate is associated with higher mortality in patients with atrial fibrillation (AF): Results from the outcomes registry for better informed treatment of AF (ORBIT-AF)

Journal of the American Heart Association

Volumn 4, Issue 9, 2015, Pages

  Steinberg, Benjamin A ^a,b   Kim, Sunghee ^b   Thomas, Laine ^b   Fonarow, Gregg C ^c   Gersh, Bernard J ^d   Holmqvist, Fredrik ^b   Hylek, Elaine ^e   Kowey, Peter R ^f   Mahaffey, Kenneth W ^g   Naccarelli, Gerald ^h   Reiffel, James A ⁱ   Chang, Paul ^j   Peterson, Eric D ^a,b   Piccini, Jonathan P ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MAYO CLINIC   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h PENN STATE COLLEGE OF MEDICINE   (United States)

ⁱ Columbia University College of Physicians and Surgeons ^*  (United States)

^j JANSSEN RESEARCH AND DEVELOPMENT   (United States)

more..

Author keywords

Atrial fibrillation; Heart rate; Outcomes; Rate control

Indexed keywords

ANTICOAGULANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; ANTIARRHYTHMIC AGENT;

AFRICAN AMERICAN; AGED; ARTICLE; ATRIAL FIBRILLATION; BLACK PERSON; CAUCASIAN; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE REGISTRY; DISEASE SEVERITY; EUROPEAN HEART RHYTHM ASSOCIATION SYMPTOM SCORE; FEMALE; HEALTH STATUS; HEART MUSCLE REVASCULARIZATION; HEART RATE; HEMATOCRIT; HISPANIC; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPENSITY SCORE; SCORING SYSTEM; SENSITIVITY ANALYSIS; SINUS NODE DISEASE; VERY ELDERLY; CHI SQUARE DISTRIBUTION; DRUG EFFECTS; EPIDEMIOLOGY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REGISTER; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CHI-SQUARE DISTRIBUTION; FEMALE; HEART RATE; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 85006201478     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.115.002031     Document Type: Article

References (19)

1. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104:1534-1539.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
3. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study G. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-1840.
4. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-1833.
5. Steinberg BA, Holmes DN, Ezekowitz MD, Fonarow GC, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J, Chang P, Peterson ED, Piccini JP. Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF) registry. Am Heart J. 2013;165:622-629.
6. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van den Berg MP. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363-1373.
7. Dorian P. Rate control in atrial fibrillation. N Engl J Med. 2010;362:1439-1441.
8. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; Guidelines ESCCfP. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719-2747.
9. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; Members AATF. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130:e199-e267.
10. Piccini JP, Fraulo ES, Ansell JE, Fonarow GC, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Thomas LE, Kong MH, Lopes RD, Mills RM, Peterson ED. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J. 2011;162:606-612.e601.
11. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692-694.
12. Piccini JP, Kim S, Steinberg BA, Holmes D, Ansell J, Fonarow G, Gersh B, Hylek E, Kowey PR, Mahaffey KW, Thomas L, Chang P, Peterson E. Quality of care, symptoms, and 1 year outcomes for women vs men with atrial fibrillation:primary results from the ORBIT-AF registry. J Am Coll Cardiol. 2013; Abstract:751-758.
13. Steinberg BA, Kim S, Piccini JP, Fonarow GC, Lopes RD, Thomas L, Ezekowitz MD, Ansell J, Kowey P, Singer DE, Gersh B, Mahaffey KW, Hylek E, Go AS, Chang P, Peterson ED; Investigators O-A, Patients. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF) Registry. Circulation. 2013;128:721-728.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
15. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA III, Page RL, Ezekowitz MD, Slotwiner DJ, Jackman WM, Stevenson WG, Tracy CM, Fuster V, Ryden LE, Cannom DS, Le Heuzey JY, Crijns HJ, Olsson SB, Prystowsky EN, Halperin JL, Tamargo JL, Kay GN, Jacobs AK, Anderson JL, Albert N, Hochman JS, Buller CE, Kushner FG, Creager MA, Ohman EM, Ettinger SM, Guyton RA, Tarkington LG, Yancy CW. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123:104-123.
16. Packer DL, Bardy GH, Worley SJ, Smith MS, Cobb FR, Coleman RE, Gallagher JJ, German LD. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol. 1986;57:563-570.
17. Smit MD, Crijns HJGM, Tijssen JGP, Hillege HL, Alings M, Tuininga YS, Groenveld HF, Van den Berg MP, Van Veldhuisen DJ, Van Gelder IC; RACE II Investigators. Effect of lenient versus strict rate control on cardiac remodeling in patients with atrial fibrillation: data of the RACE II (rate control efficacy in permanent atrial fibrillation II) study. J Am Coll Cardiol. 2011;58:942-949.
18. Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE, Crijns HJ; Race, Investigators A. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace. 2006;8:935-942.
19. Van Gelder IC, Van Veldhuisen DJ, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Bosker HA, Cornel JH, Kamp O, Veeger NJ, Volbeda M, Rienstra M, Ranchor AV, TenVergert EM, Van den Berg MP. Rate control efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE II. Am Heart J. 2006;152:420-426.